(Reuters) - WASHINGTON, June 15 - A new pill for a
debilitating and often life-threatening lung disease won
approval from U.S. health officials on Friday.
Letairis from Gilead Sciences Inc. received Food
and Drug Administration clearance for treating pulmonary
arterial hypertension, or PAH.
Read more at Reuters.com Government Filings News
debilitating and often life-threatening lung disease won
approval from U.S. health officials on Friday.
Letairis from Gilead Sciences Inc. received Food
and Drug Administration clearance for treating pulmonary
arterial hypertension, or PAH.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment